{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:11:31Z","timestamp":1790655091359,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/s12967-014-0340-9","type":"journal-article","created":{"date-parts":[[2014,12,9]],"date-time":"2014-12-09T13:50:22Z","timestamp":1418133022000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Aldosterone synthase inhibition: cardiorenal protection in animal disease models and translation of hormonal effects to human subjects"],"prefix":"10.1186","volume":"12","author":[{"given":"Jo\u00ebl","family":"M\u00e9nard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean F","family":"Rigel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arco Y","family":"Jeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Beil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chii-Whei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Leung-Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"LaSala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiqing","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Rebello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P","family":"Dole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,12,10]]},"reference":[{"key":"340_CR1","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0889-8529(18)30106-3","volume":"23","author":"GH Williams","year":"1994","unstructured":"Williams GH: Essential hypertension as an endocrine disease. Endocrinol Metab Clin North Am. 1994, 23: 429-444.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"340_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10741-005-2346-0","volume":"10","author":"HV Joffe","year":"2005","unstructured":"Joffe HV, Adler GK: Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation. Heart Fail Rev. 2005, 10: 31-37. 10.1007\/s10741-005-2346-0.","journal-title":"Heart Fail Rev"},{"key":"340_CR3","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999, 341: 709-717. 10.1056\/NEJM199909023411001.","journal-title":"N Engl J Med"},{"key":"340_CR4","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003, 348: 1309-1321. 10.1056\/NEJMoa030207.","journal-title":"N Engl J Med"},{"key":"340_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B: Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011, 364: 11-21. 10.1056\/NEJMoa1009492.","journal-title":"N Engl J Med"},{"key":"340_CR6","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/0002-9343(73)90128-9","volume":"55","author":"JH Laragh","year":"1973","unstructured":"Laragh JH: Vasoconstriction-volume analysis for understanding and treating hypertension: the use of renin and aldosterone profiles. Am J Med. 1973, 55: 261-274. 10.1016\/0002-9343(73)90128-9.","journal-title":"Am J Med"},{"key":"340_CR7","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/clpt.1980.75","volume":"27","author":"LE Ramsay","year":"1980","unstructured":"Ramsay LE, Hettiarachchi J, Fraser R, Morton JJ: Amiloride, spironolactone, and potassium chloride in thiazide-treated hypertensive patients. Clin Pharmacol Ther. 1980, 27: 533-543. 10.1038\/clpt.1980.75.","journal-title":"Clin Pharmacol Ther"},{"key":"340_CR8","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1161\/01.HYP.0000205225.88721.2c","volume":"47","author":"TY Chun","year":"2006","unstructured":"Chun TY, Pratt JH: Nongenomic renal effects of aldosterone: dependency on NO and genomic actions. Hypertension. 2006, 47: 636-637. 10.1161\/01.HYP.0000205225.88721.2c.","journal-title":"Hypertension"},{"key":"340_CR9","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.steroids.2005.02.004","volume":"70","author":"AS Mihailidou","year":"2005","unstructured":"Mihailidou AS, Funder JW: Nongenomic effects of mineralocorticoid receptor activation in the cardiovascular system. Steroids. 2005, 70: 347-351. 10.1016\/j.steroids.2005.02.004.","journal-title":"Steroids"},{"key":"340_CR10","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1146\/annurev.physiol.59.1.365","volume":"59","author":"M Wehling","year":"1997","unstructured":"Wehling M: Specific, nongenomic actions of steroid hormones. Annu Rev Physiol. 1997, 59: 365-393. 10.1146\/annurev.physiol.59.1.365.","journal-title":"Annu Rev Physiol"},{"key":"340_CR11","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/eurheartj\/16.suppl_N.103","volume":"16 Suppl N","author":"AD Struthers","year":"1995","unstructured":"Struthers AD: Aldosterone escape during ACE inhibitor therapy in chronic heart failure. Eur Heart J. 1995, 16 Suppl N: 103-106. 10.1093\/eurheartj\/16.suppl_N.103.","journal-title":"Eur Heart J"},{"key":"340_CR12","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1677\/joe.0.0910457","volume":"91","author":"J Staessen","year":"1981","unstructured":"Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A: Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol. 1981, 91: 457-465. 10.1677\/joe.0.0910457.","journal-title":"J Endocrinol"},{"key":"340_CR13","doi-asserted-by":"publisher","first-page":"E11","DOI":"10.1152\/ajpendo.00100.2011","volume":"301","author":"MD Taves","year":"2011","unstructured":"Taves MD, Gomez-Sanchez CE, Soma KK: Extra-adrenal glucocorticoids and mineralocorticoids: evidence for local synthesis, regulation, and function. Am J Physiol Endocrinol Metab. 2011, 301: E11-E24. 10.1152\/ajpendo.00100.2011.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"340_CR14","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1161\/01.CIR.99.20.2694","volume":"99","author":"JS Silvestre","year":"1999","unstructured":"Silvestre JS, Heymes C, Oubenaissa A, Robert V, Aupetit-Faisant B, Carayon A, Swynghedauw B, Delcayre C: Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation. 1999, 99: 2694-2701. 10.1161\/01.CIR.99.20.2694.","journal-title":"Circulation"},{"key":"340_CR15","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.mce.2003.10.013","volume":"217","author":"PC White","year":"2004","unstructured":"White PC: Aldosterone synthase deficiency and related disorders. Mol Cell Endocrinol. 2004, 217: 81-87. 10.1016\/j.mce.2003.10.013.","journal-title":"Mol Cell Endocrinol"},{"key":"340_CR16","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1210\/edrv-2-4-495","volume":"2","author":"JD Veldhuis","year":"1981","unstructured":"Veldhuis JD, Melby JC: Isolated aldosterone deficiency in man: acquired and inborn errors in the biosynthesis or action of aldosterone. Endocr Rev. 1981, 2: 495-517. 10.1210\/edrv-2-4-495.","journal-title":"Endocr Rev"},{"key":"340_CR17","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1021\/ml400324c","volume":"4","author":"EL Meredith","year":"2013","unstructured":"Meredith EL, Ksander G, Monovich LG, Papillon JP, Liu Q, Miranda K, Morris P, Rao C, Burgis R, Capparelli M, Hu QY, Singh A, Rigel DF, Jeng AY, Beil M, Fu F, Hu CW, LaSala D: Discovery and in vivo evaluation of potent dual CYP11B2 (Aldosterone Synthase) and CYP11B1 inhibitors. ACS Med Chem Lett. 2013, 4: 1203-1207. 10.1021\/ml400324c.","journal-title":"ACS Med Chem Lett"},{"key":"340_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.pharmthera.2005.07.006","volume":"111","author":"T Hakki","year":"2006","unstructured":"Hakki T, Bernhardt R: CYP17- and CYP11B-dependent steroid hydroxylases as drug development targets. Pharmacol Ther. 2006, 111: 27-52. 10.1016\/j.pharmthera.2005.07.006.","journal-title":"Pharmacol Ther"},{"key":"340_CR19","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1210\/jc.2013-2117","volume":"99","author":"X Bertagna","year":"2014","unstructured":"Bertagna X, Pivonello R, Fleseriu M, Zhang Y, Robinson P, Taylor A, Watson CE, Maldonado M, Hamrahian AH, Boscaro M, Biller BM: LCI699, a potent 11beta-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing\u2019s disease: results from a multicenter, proof-of-concept study. J Clin Endocrinol Metab. 2014, 99: 1375-1383. 10.1210\/jc.2013-2117.","journal-title":"J Clin Endocrinol Metab"},{"key":"340_CR20","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ab.2009.07.025","volume":"394","author":"D LaSala","year":"2009","unstructured":"LaSala D, Shibanaka Y, Jeng AY: Coexpression of CYP11B2 or CYP11B1 with adrenodoxin and adrenodoxin reductase for assessing the potency and selectivity of aldosterone synthase inhibitors. Anal Biochem. 2009, 394: 56-61. 10.1016\/j.ab.2009.07.025.","journal-title":"Anal Biochem"},{"key":"340_CR21","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1124\/jpet.110.167148","volume":"334","author":"DF Rigel","year":"2010","unstructured":"Rigel DF, Fu F, Beil M, Hu CW, Liang G, Jeng AY: Pharmacodynamic and pharmacokinetic characterization of the aldosterone synthase inhibitor FAD286 in two rodent models of hyperaldosteronism: comparison with the 11beta-hydroxylase inhibitor metyrapone. J Pharmacol Exp Ther. 2010, 334: 232-243. 10.1124\/jpet.110.167148.","journal-title":"J Pharmacol Exp Ther"},{"key":"340_CR22","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1161\/01.HYP.29.1.428","volume":"29","author":"J Bohlender","year":"1997","unstructured":"Bohlender J, Fukamizu A, Lippoldt A, Nomura T, Dietz R, Menard J, Murakami K, Luft FC, Ganten D: High human renin hypertension in transgenic rats. Hypertension. 1997, 29: 428-434. 10.1161\/01.HYP.29.1.428.","journal-title":"Hypertension"},{"key":"340_CR23","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1177\/1470320310392618","volume":"12","author":"R St-Jacques","year":"2011","unstructured":"St-Jacques R, Toulmond S, Auger A, Binkert C, Cromlish W, Fischli W, Harris J, Hess P, Jie L, Liu S, Riendeau D, Steiner B, Percival MD: Characterization of a stable, hypertensive rat model suitable for the consecutive evaluation of human renin inhibitors. J Renin Angiotensin Aldosterone Syst. 2011, 12: 133-145. 10.1177\/1470320310392618.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"340_CR24","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1177\/009286159502900324","volume":"29","author":"K Gough","year":"1995","unstructured":"Gough K, Hutchison M, Keene O, Byrom W, Ellis S, Lacey L, McKellar J: Assessment of dose proportionality: report from the Statisticians in the Pharmaceutical Industry\/Pharmacokinetics UK Joint Working Party. Drug Inf J. 1995, 29: 1039-1048.","journal-title":"Drug Inf J"},{"key":"340_CR25","doi-asserted-by":"crossref","unstructured":"Cai TQ, Stribling S, Tong X, Xu L, Wisniewski T, Fontenot JA, Struthers M, Akinsanya KO: Rhesus monkey model for concurrent analyses of in vivo selectivity, pharmacokinetics and pharmacodynamics of aldosterone synthase inhibitors.J Pharmacol Toxicol Methods 2014, doi:10.1016\/j.vascn.2014.09.011.,","DOI":"10.1016\/j.vascn.2014.09.011"},{"key":"340_CR26","doi-asserted-by":"crossref","unstructured":"Hu Q, Yin L, Hartmann RW: Aldosterone synthase inhibitors as promising treatments for mineralocorticoid dependent cardiovascular and renal diseases.J Med Chem 2014, e-pub ahead of print, doi:10.1021\/jm401430e.,","DOI":"10.1021\/jm401430e"},{"key":"340_CR27","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1172\/JCI108813","volume":"60","author":"T Berl","year":"1977","unstructured":"Berl T, Linas SL, Aisenbrey GA, Anderson RJ: On the mechanism of polyuria in potassium depletion. The role of polydipsia. J Clin Invest. 1977, 60: 620-625. 10.1172\/JCI108813.","journal-title":"J Clin Invest"},{"key":"340_CR28","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1161\/CIRCULATIONAHA.104.521625","volume":"111","author":"A Fiebeler","year":"2005","unstructured":"Fiebeler A, Nussberger J, Shagdarsuren E, Rong S, Hilfenhaus G, Al-Saadi N, Dechend R, Wellner M, Meiners S, Maser-Gluth C, Jeng AY, Webb RL, Luft FC, Muller DN: Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation. 2005, 111: 3087-3094. 10.1161\/CIRCULATIONAHA.104.521625.","journal-title":"Circulation"},{"key":"340_CR29","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1161\/01.RES.0000180753.63183.95","volume":"97","author":"LJ Min","year":"2005","unstructured":"Min LJ, Mogi M, Li JM, Iwanami J, Iwai M, Horiuchi M: Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells. Circ Res. 2005, 97: 434-442. 10.1161\/01.RES.0000180753.63183.95.","journal-title":"Circ Res"},{"key":"340_CR30","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1161\/ATVBAHA.108.168021","volume":"28","author":"AC Montezano","year":"2008","unstructured":"Montezano AC, Callera GE, Yogi A, He Y, Tostes RC, He G, Schiffrin EL, Touyz RM: Aldosterone and angiotensin II synergistically stimulate migration in vascular smooth muscle cells through c-Src-regulated redox-sensitive RhoA pathways. Arterioscler Thromb Vasc Biol. 2008, 28: 1511-1518. 10.1161\/ATVBAHA.108.168021.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"340_CR31","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1113\/expphysiol.2008.045914","volume":"95","author":"EP Gomez-Sanchez","year":"2010","unstructured":"Gomez-Sanchez EP: The mammalian mineralocorticoid receptor: tying down a promiscuous receptor. Exp Physiol. 2010, 95: 13-18. 10.1113\/expphysiol.2008.045914.","journal-title":"Exp Physiol"},{"key":"340_CR32","doi-asserted-by":"publisher","first-page":"5179","DOI":"10.1021\/jm500140c","volume":"57","author":"L Yin","year":"2014","unstructured":"Yin L, Hu Q, Emmerich J, Lo MM, Metzger E, Ali A, Hartmann RW: Novel pyridyl- or isoquinolinyl-substituted indolines and indoles as potent and selective aldosterone synthase inhibitors. J Med Chem. 2014, 57: 5179-5189. 10.1021\/jm500140c.","journal-title":"J Med Chem"},{"key":"340_CR33","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/ndt\/gfs388","volume":"28","author":"M Azizi","year":"2013","unstructured":"Azizi M, Amar L, Menard J: Aldosterone synthase inhibition in humans. Nephrol Dial Transplant. 2013, 28: 36-43. 10.1093\/ndt\/gfs388.","journal-title":"Nephrol Dial Transplant"},{"key":"340_CR34","doi-asserted-by":"publisher","first-page":"9424","DOI":"10.1073\/pnas.95.16.9424","volume":"95","author":"S Berger","year":"1998","unstructured":"Berger S, Bleich M, Schmid W, Cole TJ, Peters J, Watanabe H, Kriz W, Warth R, Greger R, Schutz G: Mineralocorticoid receptor knockout mice: pathophysiology of Na+ metabolism. Proc Natl Acad Sci U S A. 1998, 95: 9424-9429. 10.1073\/pnas.95.16.9424.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"340_CR35","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s004240050906","volume":"438","author":"M Bleich","year":"1999","unstructured":"Bleich M, Warth R, Schmidt-Hieber M, Schulz-Baldes A, Hasselblatt P, Fisch D, Berger S, Kunzelmann K, Kriz W, Schutz G, Greger R: Rescue of the mineralocorticoid receptor knock-out mouse. Pflugers Arch. 1999, 438: 245-254. 10.1007\/s004240050906.","journal-title":"Pflugers Arch"},{"key":"340_CR36","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1161\/01.HYP.0000249902.09036.e7","volume":"48","author":"N Makhanova","year":"2006","unstructured":"Makhanova N, Sequeira-Lopez ML, Gomez RA, Kim HS, Smithies O: Disturbed homeostasis in sodium-restricted mice heterozygous and homozygous for aldosterone synthase gene disruption. Hypertension. 2006, 48: 1151-1159. 10.1161\/01.HYP.0000249902.09036.e7.","journal-title":"Hypertension"},{"key":"340_CR37","first-page":"F544","volume":"233","author":"RG O\u2019Neil","year":"1977","unstructured":"O\u2019Neil RG, Helman SI: Transport characteristics of renal collecting tubules: influences of DOCA and diet. Am J Physiol. 1977, 233: F544-F558.","journal-title":"Am J Physiol"},{"key":"340_CR38","first-page":"F225","volume":"233","author":"LN Peterson","year":"1977","unstructured":"Peterson LN, Wright FS: Effect of sodium intake on renal potassium excretion. Am J Physiol. 1977, 233: F225-F234.","journal-title":"Am J Physiol"},{"key":"340_CR39","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.111.029892","volume":"124","author":"DA Calhoun","year":"2011","unstructured":"Calhoun DA, White WB, Krum H, Guo W, Bermann G, Trapani A, Lefkowitz MP, Menard J: Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation. 2011, 124: 1945-1955. 10.1161\/CIRCULATIONAHA.111.029892.","journal-title":"Circulation"},{"key":"340_CR40","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nrd1039","volume":"2","author":"R Brown","year":"2003","unstructured":"Brown R, Quirk J, Kirkpatrick P: Eplerenone. Nat Rev Drug Discov. 2003, 2: 177-178. 10.1038\/nrd1039.","journal-title":"Nat Rev Drug Discov"},{"key":"340_CR41","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1161\/HYPERTENSIONAHA.109.136242","volume":"54","author":"AS Mihailidou","year":"2009","unstructured":"Mihailidou AS, Le Loan TY, Mardini M, Funder JW: Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension. 2009, 54: 1306-1312. 10.1161\/HYPERTENSIONAHA.109.136242.","journal-title":"Hypertension"},{"key":"340_CR42","doi-asserted-by":"publisher","first-page":"H1242","DOI":"10.1152\/ajpheart.01400.2006","volume":"293","author":"R Fischer","year":"2007","unstructured":"Fischer R, Dechend R, Gapelyuk A, Shagdarsuren E, Gruner K, Gruner A, Gratze P, Qadri F, Wellner M, Fiebeler A, Dietz R, Luft FC, Muller DN, Schirdewan A: Angiotensin II-induced sudden arrhythmic death and electrical remodeling. Am J Physiol Heart Circ Physiol. 2007, 293: H1242-H1253. 10.1152\/ajpheart.01400.2006.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"340_CR43","first-page":"F811","volume":"255","author":"DB Young","year":"1988","unstructured":"Young DB: Quantitative analysis of aldosterone\u2019s role in potassium regulation. Am J Physiol. 1988, 255: F811-F822.","journal-title":"Am J Physiol"},{"key":"340_CR44","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.1210\/jc.2008-0710","volume":"93","author":"R Kazlauskaite","year":"2008","unstructured":"Kazlauskaite R, Evans AT, Villabona CV, Abdu TA, Ambrosi B, Atkinson AB, Choi CH, Clayton RN, Courtney CH, Gonc EN, Maghnie M, Rose SR, Soule SG, Tordjman K: Corticotropin tests for hypothalamic-pituitary- adrenal insufficiency: a metaanalysis. J Clin Endocrinol Metab. 2008, 93: 4245-4253. 10.1210\/jc.2008-0710.","journal-title":"J Clin Endocrinol Metab"},{"key":"340_CR45","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1172\/JCI103988","volume":"38","author":"WS Coppage Jr","year":"1959","unstructured":"Coppage WS, Island D, Smith M, Liddle GW: Inhibition of aldosterone secretion and modification of electrolyte excretion in man by a chemical inhibitor of 11 beta-hydroxylation. J Clin Invest. 1959, 38: 2101-2110. 10.1172\/JCI103988.","journal-title":"J Clin Invest"},{"key":"340_CR46","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1210\/jcem-18-8-906","volume":"18","author":"GW Liddle","year":"1958","unstructured":"Liddle GW, Island D, Lance EM, Harris AP: Alterations of adrenal steroid patterns in man resulting from treatment with a chemical inhibitor of 11 beta-hydroxylation. J Clin Endocrinol Metab. 1958, 18: 906-912. 10.1210\/jcem-18-8-906.","journal-title":"J Clin Endocrinol Metab"},{"key":"340_CR47","doi-asserted-by":"publisher","first-page":"A61.E582","DOI":"10.1016\/S0735-1097(10)60583-9","volume":"55","author":"WB White","year":"2010","unstructured":"White WB, Calhoun DA, Krum H, Guo W, Trapani AJ, Lefkowitz M, Menard J: Blockade of aldosterone production as a novel approach to the management of high blood pressure: efficacy and tolerability of the aldosterone synthase inhibitor LCI699 in patients with stage 1-2 hypertension. J Am Coll Cardiol. 2010, 55: A61.E582-","journal-title":"J Am Coll Cardiol"},{"key":"340_CR48","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1161\/HYPERTENSIONAHA.110.157271","volume":"56","author":"L Amar","year":"2010","unstructured":"Amar L, Azizi M, Menard J, Peyrard S, Watson C, Plouin PF: Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism. Hypertension. 2010, 56: 831-838. 10.1161\/HYPERTENSIONAHA.110.157271.","journal-title":"Hypertension"},{"key":"340_CR49","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1210\/jc.2007-2734","volume":"93","author":"BM Biller","year":"2008","unstructured":"Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vance ML, Wass JA, Boscaro M: Treatment of adrenocorticotropin-dependent Cushing\u2019s syndrome: a consensus statement. J Clin Endocrinol Metab. 2008, 93: 2454-2462. 10.1210\/jc.2007-2734.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-014-0340-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12967-014-0340-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-014-0340-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-014-0340-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T02:55:05Z","timestamp":1630551305000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-014-0340-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["340"],"URL":"https:\/\/doi.org\/10.1186\/s12967-014-0340-9","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"19 September 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"340"}}